Herein, we describe an asymmetric assembly of ortho-aromatic diamines and formyl tethered Michael acceptors forming chiral fused benzimidazoles. A cinchona-alkaloid-derived bifunctional squaramide catalyst enables the methodology through on-site dihydrobenzimidazole formation followed by an aza-Michael addition/oxidation cascade. This protocol stands out for its excellent catalytic efficiency over the background reaction and its mild conditions, making it more practical. Various Michael acceptors, including enones, ester, and thioester, were successful substrates in this study. Additionally, this methodology has demonstrated scalability and successfully showcased postsynthetic transformations.B enzimidazole is a privileged structural motif frequently found in marketed drug molecules, such as Omeprazole, Albendazole, Liarozole, Telmisartan, and Mibefradil. 1 This heterocyclic pharmacophore exhibits diverse biological properties, including anti-inflammatory, anticancer, antimicrobial, antiviral, antifungal, and so on. 2 Particularly, tricyclic and 1,2disubstituted chiral benzimidazole derivatives demonstrate a broad spectrum of pharmaceutical, biological activities (Figure 1A). 3 For instance, dihydropyrrole-fused benzimidazole